The aim of this study was to determine whether noninitial rituximab doses can be safely administered by a rapid, 90-minute infusion for patients with a CD20-positive B-cell malignancy with or without steroid-containing chemotherapy regimens. Thirteen patients were enrolled in this study for a total of 32 rapid rituximab infusions, all of which were administered in an outpatient setting. The rapid rituximab infusions were well tolerated by 12 of the 13 patients in 31 of 32 infusions. There was one grade 3 reaction of prolonged hypotension, tachycardia, and fever, which resolved within 24 hours. No other symptomatic infusion reactions occurred. These results support previously reported data affirming the safety and tolerability of a rapid, 90-minute infusion for noninitial doses of rituximab in patients with CD20-positive B-cell malignancy. Adopting a rapid infusion schedule would benefit patients and the institution by reducing clinic chair time for each dose by 1.5-2 hours, compared with standard infusion times.
ASJC Scopus subject areas